The GLAUrious is clinically testing and validating the novel External Automatic Glaucoma Laser (EAGLE) device developed and patented by BELKIN Laser Ltd with the goal of providing accessible first-line treatment for glaucoma.
GLAUrious project aims to ease commercialization of the EAGLE device by securing clinical prototype validation, streamlining commercial production, optimizing component costs, disseminating to key opinion leaders and distributors, and refining commercial strategy.
The multidisciplinary GLAUrious Consortium is led by Queen's University Belfast (Northern Ireland, UK) consists of four additional partners- BELKIN Laser Ltd (Israel), Frankfurt Laser Company (Germany), MCI bvba (Belgium), Eye clinic University of Genova (Italy).
During the last year the advanced clinical prototype was produced and validated to meet the requirements of UK and Italian authorities’ towards prospective randomized clinical study initiation (trial registered at ISRCTN # 14033075).
